Yimmugo Lots Withdrawn

Biotest AG initiated a voluntary withdrawal for certain lots of Yimmugo^® (immune globulin IV, human-dira), 10% liquid, on Aug. 13, 2026. The withdrawal was initiated as a precautionary measure due to an increased rate of allergic or hypersensitivity-type reactions associated with specific lots, including a small number of medically significant reactions. Hypersensitivity and anaphylactic/anaphylactoid reactions are known risks associated with immune globulin products. Yimmugo is FDA-approved for replacement therapy in adults with primary humoral immunodeficiency (PI). For more information about this withdrawal, see here.